A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus.
Benjamin BurggraafNadine M C PouwSalvador Fernández ArroyoLeonie C van Vark-van der ZeeGert-Jan M van de GeijnErwin BirnieJeannine HuisbrinkEllen M van der ZwanMonique T MulderPatrick C N RensenWouter W de HerderManuel Castro CabezasPublished in: Diabetes, obesity & metabolism (2020)
In addition to the well-known LDL-C-reducing effects, 6 weeks of alirocumab treatment lowered both fasting and postprandial plasma TG levels by reducing the TG levels in VLDL and LDL and the concentration of intestinal remnants.
Keyphrases
- blood glucose
- end stage renal disease
- low density lipoprotein
- newly diagnosed
- type diabetes
- ejection fraction
- chronic kidney disease
- placebo controlled
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- glycemic control
- radiation therapy
- clinical trial
- squamous cell carcinoma
- patient reported outcomes
- study protocol
- phase ii
- rectal cancer
- patient reported
- phase ii study
- open label
- locally advanced